Insulet (NSDQ:PODD) said today that its Omnipod insulin management system is available in Europe for use with Novo Nordisk‘s (NYSE:NVO) Fiasp fast-acting insulin aspart.
Novo Nordisk’s Fiasp product enters the user’s bloodstream two times faster than NovoRapid and is designed to match a healthy body’s response to a meal, according to Insulet.
Get the full story at our sister site, Drug Delivery Business News.
The post Europe OKs Novo Nordisk’s Fiasp for Insulet’s Omnipod appeared first on MassDevice.